| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Akhila Yerubandi, Jennifer E Thomas, N M Mahmudul Alam Bhuiya, Catherine Harrington, Lorenzo Villa Zapata, Joshua Caballer. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA network open. vol 7. issue 4. 2024-04-10. PMID:38598236. |
psilocybin has been studied in the treatment of depression and anxiety disorders. |
2024-04-10 |
2024-04-12 |
Not clear |
| Zarah R Haniff, Mariia Bocharova, Tim Mantingh, James J Rucker, Latha Velayudhan, David M Taylor, Allan H Young, Dag Aarsland, Anthony C Vernon, Sandrine Thure. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & therapeutics. 2024-04-07. PMID:38583670. |
the potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. |
2024-04-07 |
2024-04-10 |
Not clear |
| Zarah R Haniff, Mariia Bocharova, Tim Mantingh, James J Rucker, Latha Velayudhan, David M Taylor, Allan H Young, Dag Aarsland, Anthony C Vernon, Sandrine Thure. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & therapeutics. 2024-04-07. PMID:38583670. |
in this context, psilocybin, a serotonergic agonist with rapid-acting antidepressant properties has the potential to ameliorate intersecting pathophysiological processes relevant for both major depression and neurodegenerative diseases. |
2024-04-07 |
2024-04-10 |
Not clear |
| Zarah R Haniff, Mariia Bocharova, Tim Mantingh, James J Rucker, Latha Velayudhan, David M Taylor, Allan H Young, Dag Aarsland, Anthony C Vernon, Sandrine Thure. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & therapeutics. 2024-04-07. PMID:38583670. |
in this narrative review, we focus on the evidence base for the effects of psilocybin on adult hippocampal neurogenesis and microglial form and function; which may suggest that psilocybin has the potential to modulate multiple mechanisms of action, and may have implications in altering the progression from major depression to dementia in those at risk. |
2024-04-07 |
2024-04-10 |
Not clear |
| Evana López, Hampus Yngwe, Maria Beckman, Mikael Tiger, Fredrik Hieronymus, Johan Lundber. [Psychedelic psychiatry]. Lakartidningen. vol 121. 2024-04-04. PMID:38572715. |
this review focuses on the psychedelic compound psilocybin, a serotonin-2a-receptor agonist that has been seen to reduce depression and anxiety in patients after administration of only a single dose, with effects lasting several weeks. |
2024-04-04 |
2024-04-06 |
Not clear |
| Evana López, Hampus Yngwe, Maria Beckman, Mikael Tiger, Fredrik Hieronymus, Johan Lundber. [Psychedelic psychiatry]. Lakartidningen. vol 121. 2024-04-04. PMID:38572715. |
recent findings from phase ii studies suggest that psilocybin treatment for depression is safe and efficacious. |
2024-04-04 |
2024-04-06 |
Not clear |
| Gia Han Le, Sabrina Wong, Sebastian Badulescu, Hezekiah Au, Joshua D Di Vincenzo, Hartej Gill, Lee Phan, Taeho Greg Rhee, Roger Ho, Kayla M Teopiz, Angela T H Kwan, Joshua D Rosenblat, Rodrigo B Mansur, Roger S McIntyr. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal of affective disorders. 2024-04-03. PMID:38570038. |
spectral signatures of psilocybin, lysergic acid diethylamide (lsd) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: a systematic review. |
2024-04-03 |
2024-04-06 |
human |
| Jesse Hudspeth, Kai Rogge, Sebastian Dörner, Maximilian Müll, Dirk Hoffmeister, Bernhard Rupp, Sebastiaan Werte. Methyl transfer in psilocybin biosynthesis. Nature communications. vol 15. issue 1. 2024-03-29. PMID:38548735. |
psilocybin, the natural hallucinogen produced by psilocybe ("magic") mushrooms, holds great promise for the treatment of depression and several other mental health conditions. |
2024-03-29 |
2024-03-31 |
Not clear |
| David Erritzoe, Tommaso Barba, Meg J Spriggs, Fernando E Rosas, David J Nutt, Robin Carhart-Harri. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. Journal of psychopharmacology (Oxford, England). 2024-03-23. PMID:38520045. |
effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. |
2024-03-23 |
2024-03-26 |
human |
| David Erritzoe, Tommaso Barba, Meg J Spriggs, Fernando E Rosas, David J Nutt, Robin Carhart-Harri. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. Journal of psychopharmacology (Oxford, England). 2024-03-23. PMID:38520045. |
there is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. |
2024-03-23 |
2024-03-26 |
human |
| Jakub Vohryzek, Joana Cabral, Louis-David Lord, Henrique M Fernandes, Leor Roseman, David J Nutt, Robin L Carhart-Harris, Gustavo Deco, Morten L Kringelbac. Brain dynamics predictive of response to psilocybin for treatment-resistant depression. Brain communications. vol 6. issue 2. 2024-03-22. PMID:38515439. |
brain dynamics predictive of response to psilocybin for treatment-resistant depression. |
2024-03-22 |
2024-03-24 |
Not clear |
| Jakub Vohryzek, Joana Cabral, Louis-David Lord, Henrique M Fernandes, Leor Roseman, David J Nutt, Robin L Carhart-Harris, Gustavo Deco, Morten L Kringelbac. Brain dynamics predictive of response to psilocybin for treatment-resistant depression. Brain communications. vol 6. issue 2. 2024-03-22. PMID:38515439. |
psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. |
2024-03-22 |
2024-03-24 |
Not clear |
| Yasir Çatal, Georg Northof. Where do the symptoms come from in depression? Topography and dynamics matter. Brain communications. vol 6. issue 2. 2024-03-22. PMID:38515441. |
this scientific commentary refers to 'brain dynamics predictive of response to psilocybin for treatment-resistant depression', by vohryzek |
2024-03-22 |
2024-03-24 |
Not clear |
| Adam W Levin, Rafaelle Lancelotta, Nathan D Sepeda, Natalie Gukasyan, Sandeep Nayak, Theodore L Wagener, Frederick S Barrett, Roland R Griffiths, Alan K Davi. The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PloS one. vol 19. issue 3. 2024-03-14. PMID:38483940. |
we examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (pat) trial changed over time and whether there were relationships between alliance, acute psilocybin experiences, and depression outcomes. |
2024-03-14 |
2024-03-17 |
human |
| Adam W Levin, Rafaelle Lancelotta, Nathan D Sepeda, Natalie Gukasyan, Sandeep Nayak, Theodore L Wagener, Frederick S Barrett, Roland R Griffiths, Alan K Davi. The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PloS one. vol 19. issue 3. 2024-03-14. PMID:38483940. |
stronger total alliance one week after the final psilocybin session predicted depression scores at 4 weeks (r = -.85, p < .001), 3 months (r = -.52, p = .010), 6 months (r = -.77, p < .001), and 12 months (r = -.61, p = .001) post-intervention. |
2024-03-14 |
2024-03-17 |
human |
| Shuping Fang, Xin Yang, Wei Zhan. Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. Frontiers in psychiatry. vol 15. 2024-03-01. PMID:38426002. |
efficacy and acceptability of psilocybin for primary or secondary depression: a systematic review and meta-analysis of randomized controlled trials. |
2024-03-01 |
2024-03-03 |
Not clear |
| Shuping Fang, Xin Yang, Wei Zhan. Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. Frontiers in psychiatry. vol 15. 2024-03-01. PMID:38426002. |
in this study, we aim to evaluate the efficacy, acceptability and tolerability of psilocybin in the treatment of primary (major depressive disorder) or secondary (experiencing distress related to life-threatening diagnoses and terminal illness) depression. |
2024-03-01 |
2024-03-03 |
Not clear |
| Débora Copa, David Erritzoe, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, Enzo Tagliazucch. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. Journal of affective disorders. 2024-02-29. PMID:38423367. |
predicting the outcome of psilocybin treatment for depression from baseline fmri functional connectivity. |
2024-02-29 |
2024-03-03 |
Not clear |
| Débora Copa, David Erritzoe, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, Enzo Tagliazucch. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. Journal of affective disorders. 2024-02-29. PMID:38423367. |
psilocybin is a serotonergic psychedelic drug under assessment as a potential therapy for treatment-resistant and major depression. |
2024-02-29 |
2024-03-03 |
Not clear |
| Salma Laabi, Claire LeMmon, Callie Vogel, Mariana Chacon, Victor M Jimene. Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights. International immunopharmacology. vol 130. 2024-02-24. PMID:38401463. |
a decade of clinical research has indicated psilocybin's effectiveness in treating various neuropsychiatric disorders, such as depression and substance abuse. |
2024-02-24 |
2024-02-27 |
Not clear |